QNCX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.180

-35.71%

-0.185

-45.59%

-0.188

-44.85%

Estimates Revision

Stock Price

Go Up

+31.86%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast QNCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNCX is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

6.00

Averages

8.00

High

10.00

Current: 0.000

Low

6.00

Averages

8.00

High

10.00

D. Boral Capital

Jason Kolbert

Buy

maintain

$4 -> $5

2025-12-15

Reason

D. Boral Capital

Jason Kolbert

Price Target

$4 -> $5

2025-12-15

maintain

Buy

Reason

D. Boral Capital analyst Jason Kolbert raised the firm's price target on Quince Therapeutics to $5 from $4 and keeps a Buy rating on the shares after the company said the last patient has completed their last visit in the pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate in patients with Ataxia-Telangiectasia. The firm cites the rolling of its valuation metrics out a year for the target bump.

Citizens JMP

Outperform

downgrade

$9 -> $8

2025-08-12

Reason

Citizens JMP

Price Target

$9 -> $8

2025-08-12

downgrade

Outperform

Reason

Citizens JMP lowered the firm's price target on Quince Therapeutics to $8 from $9 and keeps an Outperform rating on the shares. The firm is impressed with management's execution in completing enrollment for the pivotal NEAT trial, which is set up for success, the analyst tells investors in a research note.

Citizens JMP

Outperform

initiated

2025-08-05

Reason

Citizens JMP

Price Target

2025-08-05

initiated

Outperform

Reason

Citizens JMP initiated coverage of Quince Therapeutics with an Outperform rating and $9 price target. The firm says Quince is using its Autologous Intracellular Drug Encapsulation platform to treat rare diseases using a patient's own biology. The company's lead candidate eDSP offers a blockbuster opportunity with limited competition, the analyst tells investors in a research note. Citizens believes pipeline expansion at Quince could move quickly and drive additional share upside.

Lucid Capital

Elemer Piros

initiated

2025-07-15

Reason

Lucid Capital

Elemer Piros

Price Target

2025-07-15

initiated

Reason

Lucid Capital analyst Elemer Piros initiated coverage of Quince Therapeutics with a Buy rating and $8 price target. The company is developing chronic steroid treatments for rare diseases with "blockbuster potential," the analyst tells investors in a research note. The firm believes the company's EryDex is set to become a blockbuster treatment in the lead ataxia-telangiectasia indication alone.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$12 → $4

2025-03-25

Reason

D. Boral Capital

Jason Kolbert

Price Target

$12 → $4

2025-03-25

Maintains

Strong Buy

Reason

Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "Our Phase 3 pivotal NEAT clinical trial has exceeded 50% enrollment with 71 participants screened and 61 randomized. Recent and upcoming new site activations are expected to accelerate enrollment through our target completion date in the second quarter of 2025. Assuming target enrollment completion, topline results from the NEAT study are anticipated in the fourth quarter of 2025."

Oppenheimer

Leland Gershell

Buy

Initiates

$10

2025-03-24

Reason

Oppenheimer

Leland Gershell

Price Target

$10

2025-03-24

Initiates

Buy

Reason

Oppenheimer analyst Leland Gershell initiated coverage of Quince Therapeutics with an Outperform rating and $10 price target, ahead of the Phase 3 results in ataxia-telangiectasia, a rare, fatal pediatric neurodegenerative disorder that the firm says lacks approved therapies. The analyst sees a $1B-plus global opportunity for Quince's lead candidate EryDex and projects $200M in 2031 U.S. sales. Opco says its "enthusiasm" for the drug's development and commercial success is driven by key opinion leader checks, prior clinical data, and a pivotal design it sees as "heavily derisked."

Valuation Metrics

The current forward P/E ratio for Quince Therapeutics Inc (QNCX.O) is -4.01, compared to its 5-year average forward P/E of -4.64. For a more detailed relative valuation and DCF analysis to assess Quince Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.64

Current PE

-4.01

Overvalued PE

3.06

Undervalued PE

-12.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.51

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.43

Undervalued EV/EBITDA

-9.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

QNCX News & Events

Events Timeline

No data

News

9.0

2025-12-15Newsfilter

Quince Completes A-T Phase 3 Trial, Expects Results in Q1 2026

3.5

2025-12-10Newsfilter

Quince Therapeutics Publishes eDSP Clinical Study Results, Showcasing Broad Application Potential

4.5

2025-12-01NASDAQ.COM

Monday's Underperforming Sectors: Biotechnology, Electronic Equipment, and Products

People Also Watch

Frequently Asked Questions

What is Quince Therapeutics Inc (QNCX) stock price today?

The current price of QNCX is 2.69 USD — it has increased 0.37 % in the last trading day.

What is Quince Therapeutics Inc (QNCX)'s business?

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.

What is the price predicton of QNCX Stock?

What is Quince Therapeutics Inc (QNCX)'s revenue for the last quarter?

Quince Therapeutics Inc revenue for the last quarter amounts to -11.36M USD, increased 32.97 % YoY.

What is Quince Therapeutics Inc (QNCX)'s earnings per share (EPS) for the last quarter?

Quince Therapeutics Inc. EPS for the last quarter amounts to -10002000.00 USD, increased 36.90 % YoY.

What changes have occurred in the market's expectations for Quince Therapeutics Inc (QNCX)'s fundamentals?

The market is revising No Change the revenue expectations for QNCX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 31.86%.

How many employees does Quince Therapeutics Inc (QNCX). have?

Quince Therapeutics Inc (QNCX) has 36 emplpoyees as of January 10 2026.

What is Quince Therapeutics Inc (QNCX) market cap?

Today QNCX has the market capitalization of 149.78M USD.